Repetitive Deep Transcranial Magnetic Stimulation in Multiple Sclerosis (rTMS in MS)
Status
Conditions
Treatments
Details and patient eligibility
About
Multiple sclerosis (MS) is a chronic-inflammatory autoimmune central nervous system disorder and a leading cause of neurological disability in younger adults in Western countries. Besides "classic" neurological symptoms both depressivity and fatigue are among the most frequent symptoms in MS, affecting up to 90% of patients at onset or during the course of the disease. Neither are the psychological and immunological backgrounds of both well understood, nor are there numerous controlled therapeutic trials which would offer convincing treatment options for fatigue and depressivity in MS.
Transcranial magnetic stimulation (TMS) has been frequently used to investigate altered hemispheric and inter-hemispheric connectivity in MS. Recently, first therapeutic trials have been performed to address specific MS-related symptoms by TMS. Koch et al. demonstrated an improvement of hand dexterity following repetitive TMS, and Centonze and colleagues showed reduced spasticity following TMS.
Recently, a specific coil for the stimulation of deeper brain regions including the deep nuclei was developed, the so-called H-coil. It successfully stimulates deeper (pre-frontal) brain regions. Stimulation with this coil has been shown to be safe and well tolerated in healthy volunteers, and in patients suffering from major depression.
The aim of this project is to apply deep TMS with the H-coil to the prefrontal cortex (PFC) of MS patients. The PFC is the region at which stimulation is aimed in previous depression studies as this brain region has been shown to play a relevant role in affective disorders. It is the primary aim of this study, to evaluate the safety and tolerability of deep TMS with the H-coil in MS patients with fatigue or depressivity.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Male and female patients with clinically definite MS according to Polman
- Age 18 to 60
- EDSS 0 to 6
- Relapse-free > 30 days prior to inclusion
- Stable immunomodulatory or immunosuppressive therapy or treatment-naïve for > 3 months prior to inclusion
- In case of treatment with antidepressants: stable therapy > 3 months
- A score of ≥ 4 on the FSS (fatigue severity scale)8 or
- A score of ≥ 12 on the Beck Depression Inventory (BDI)
- Highly effective methods of birth control for females
Exclusion criteria
- Personal or family history of epilepsy, brain tumor, brain injury
- History of metallic particles in the eye or head outside the mouth
- Cardiac pacemakers, implanted neurostimulators, cochlear implants, implanted medication pumps
- History of drug or alcohol abuse
- Pregnancy
- Relapse of MS < 30 days prior to inclusion
- I.v. corticosteroid treatment < 30 days prior to inclusion
- Change of immunomodulatory therapy < 30 days prior to inclusion
- Change of antidepressant therapy < 3 months prior to inclusion
- Comedication with neuroleptics and tricyclic antidepressants (amitriptyline etc.) during the entire study
- patients with increased intracranial pressure (which lowers seizure threshold)
- intracardiac lines
- significant heart disease
- bipolar disorder
- history of stroke or other brain lesions
Trial design
Primary purpose
Allocation
Interventional model
Masking
36 participants in 3 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal